TAP accepts and reviews partnering inquiries year round
TAP collaborates with and makes equity investments in biotech companies to support the development of novel platforms, first-in-class assets addressing high unmet medical needs, emerging patient populations and orphan indications.
- Download and complete the TAP Inquiry Form
- Send the completed application and your non-confidential presentation to via email.
The approval process considers strategy, opportunities, and the potential for success.
Want to know more about TAP, please download a presentation and an information sheet for more information.
Powerful value-added benefits of a TAP partnership
It starts with an equity investment in your company, but there are many other powerful value-added benefits that companies enjoy as part of a TAP partnership.
Currently, there are more than thirty clinical trials with TAP-supported therapies, including several registration-enabling clinical studies. But companies in the TAP portfolio have a higher probability of partnering with other companies or financial institutions. Being selected for the TAP portfolio can have major benefits for companies—aside from helping to cure blood cancers, of course.
Strategy and diligence process
When determining who qualifies for inclusion in the TAP Portfolio, we consider many factors, including:
- Existing and emerging populations with high unmet needs
- Gaps in current and emerging treatment landscape
- Innovative science and first-in-class assets
- First-in-human and registration trials
Strong intellectual property, management, and finances are key factors in determining who is selected as a TAP partner.
Each year, TAP reviews opportunities from approximately 80–100 biotech companies to identify those with the highest potential to change the standard of care.
The rigorous TAP due diligence process includes five stages, including utilizing external experts (TAP Advisory Council) to assist with evaluation.
Funding only the most promising projects that have a clear path forward for patients, TAP only invests in several new projects annually, with an open partnering cycle all year long.
TAP adds value to biotech companies beyond dollars
Why do companies want to be part of TAP?
Because of active collaboration with us, TAP portfolio companies benefit from Blood Cancer United's deep cancer insight, a key opinion leader (KOL) and clinical network, drug development, and business expertise.
The TAP record of success provides scientific & investment credibility as well as visibility, enabling companies to raise additional funds.
We are grateful for the support of Blood Cancer United as part of their Therapy Acceleration Program (TAP). This new collaboration will help drive our efforts in hematological malignancies, with a focus on CMML. The TAP program is designed to accelerate the development of novel therapies, ultimately improving treatment options and outcomes for blood cancer patients
Phil Vickers, PhD
President and Chief Executive Officer, Solu Therapeutics
We are thrilled to partner with Blood Cancer United TAP in our shared mission to bring transformative therapies to AML patients.Our partnership enables us to leverage their extensive expertise in blood cancer research and patient advocacy, and to tap into their vast network of physicians, scientists, and patients to better inform our rapid development of AUTX-703. Blood Cancer United in uniquely positioned to support our objective of developing a novel, cutting edge therapy that improves patient outcomes.
Kate Yen, PhD
Founder and Chief Executive Officer, Auron Therapeutics
A Patient’s Journey: The Impact of TAP and Vyxeos
Blood Cancer United and TAP committed more than $9 million in a partnership with Celator Pharmaceuticals between 2009-2016 to advance Vyxeos® (also known as CPX-351), a dual-drug liposomal encapsulation of daunorubicin and cytarabine, through Phase 2 and Phase 3 clinical development.
Listen to this patient story of a teenage girl who was treated with Vyxeos and her battle with leukemia. Dr. Lawrence Mayer, former founder and Chief Scientific Officer of Celator Pharmaceuticals, adds his perspective and describes the role TAP played in the development of Vyxeos and the value created for Celator beyond the funding.
Vyxeos was first approved in August 2017 for adult patients with certain types of high-risk acute myeloid leukemia and in March 2021, the FDA updated the approval to include pediatric patients aged 1 year and older.
How did TAP impact the development of Elzonris®?
Blood Cancer United awarded several grants to Dr. Arthur Frankel between 1998-2008 to develop fusion protein therapies for blood cancers, including SL-401 (now known as Elzonris). TAP then partnered with Stemline Therapeutics in 2013 to support key clinical studies for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Listen to what Dr. Arthur Frankel and Peter MacDonald, SVP of Corporate & Business Development of Stemline Therapeutics, have to say about Blood Cancer United, the role TAP played in the development of Elzonris and the value TAP created for Stemline beyond the funding amount.
Elzonris® is the first approved therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer.
